FREQUENCY OF COMORBIDITY THERAPIES IN PARKINSON'S AND ALZHEIMER'S PATIENTS
Arbnore QAILI NAZIFI, Sadi BEXHETI
Abstract
Introduction: Alzheimer's disease (AD), a leading cause of dementia, is a progressive neurodegenerative disorder. This disease begins slowly, first involving the parts of the brain that control thoughts, memory and language. People with AD may have trouble remembering things that have happened recently or the names of people they know. Aim: The aim of this paper is to analyze and evaluate the frequency of comorbidity therapies in patients with Parkinson's and Alzheimer's disease. Study design: Retrospective study Method: Were involved 945 patients who were hospitalized in the Neurology Department of Skopje Clinical Hospital for the period from January 2014 to January 2024, of whom 772 patients met all the conditions for the study.
The statistical program for social sciences (SPSS) version 25.0 with license was used for data analysis. Results: Approximately 339 or 43.9% of the therapy of acetylsalicylic acid was used, Amitriptyline therapy was used by 202 or 26.2% of patients, followed by atorvastatin therapy used by 112 or 14.5% of patients, while diazepam was used by 167 patients or 21.6%, other therapy that was used by 112 or 14.5% of patients is enalapril. A smaller number of patients have used Lisinopril therapy, 53 or 6.9% of patients. Ranitidine was used by 45 or 5.8% of patients and the last therapy vitamin therapy but not least important, was used by patients who were involved in this study approximately 76 or 6.9% of patients. Conclusion: Furthermore, early diagnosis, early symptomatic treatment, and especially the introduction of neuroprotective therapies will improve the pharmacological management of Parkinson's and Alzheimer's disease.
Pages: 74 - 80